[1] NISHIDA N, GOEL A. Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma: A Systematic Review [J]. Curr Genomics, 2011, 12(2): 130-7.
[2] GAO W, KONDO Y, SHEN L, et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas [J]. Carcinogenesis, 2008, 29(10): 1901-10.
[3] FU C Y, AN N, LIU J M, et al. The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1? in liver cancer cells [J]. J Biol Chem, 2020, 295(20): 7060-74.
[4] HAN T S, BAN H S, HUR K, et al. The Epigenetic Regulation of HCC Metastasis [J]. Int J Mol Sci, 2018, 19(12).
[5] LLOVET J M, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma [J]. New Engl J Med, 2008, 359(4): 378-90.
[6] JEONG S S, TONG Y, SHA M, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma [J]. Oncotarget, 2017, 8(10): 17292-300.
[7] ALI A, ABDEL-HAFIZ H, SUHAIL M, et al. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma [J]. World J Gastroentero, 2014, 20(30): 10238-48.
[8] WILSON C L, MANN D A, BORTHWICK L A. Epigenetic reprogramming in liver fibrosis and cancer [J]. Adv Drug Deliv Rev, 2017, 121: 124-32.
[9] MORINAGA T, YASUDA H, HASHIMOTO T, et al. A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers [J]. Mol Cell Biol, 1991, 11(12): 6041-9.
[10] MIURA Y, TAM T, IDO A, et al. Cloning and Characterization of an Atbf1 Isoform That Expresses in a Neuronal Differentiation-Dependent Manner [J]. J Biol Chem, 1995, 270(45): 26840-8.
[11] ZHAO D, MA G, ZHANG X L, et al. Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity [J]. J Biol Chem, 2016, 291(24): 12809-20.
[12] PARSONS M J, BRANCACCIO M, SETHI S, et al. The Regulatory Factor ZFHX3 Modifies Circadian Function in SCN via an AT Motif-Driven Axis [J]. Cell, 2015, 162(3): 607-21.
[13] SUN X D, XING C S, FU X Y, et al. Additive Effect of Zfhx3/Atbf1 and Pten Deletion on Mouse Prostatic Tumorigenesis [J]. J Genet Genomics, 2015, 42(7): 373-82.
[14] HU Q, ZHANG B, CHEN R, et al. ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells [J]. Oncogenesis, 2019, 8(4).
[15] DONG X Y, SUN X, GUO P, et al. ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells [J]. J Biol Chem, 2010, 285(43): 32801-9.
[16] NOJIRI S, JOH T, MIURA Y, et al. ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3 [J]. Biochem Bioph Res Co, 2004, 314(1): 97-103.
[17] RAVASI T, SUZUKI H, CANNISTRACI C V, et al. An Atlas of Combinatorial Transcriptional Regulation in Mouse and Man (vol 140, pg 744, 2010) [J]. Cell, 2010, 141(2): 369-.
[18] BAXTER E, WINDLOCH K, GANNON F, et al. Epigenetic regulation in cancer progression [J]. Cell Biosci, 2014, 4.
[19] LAMBERT S A, JOLMA A, CAMPITELLI L F, et al. The Human Transcription Factors (vol 172, pg 650, 2018) [J]. Cell, 2018, 175(2): 598-9.
[20] RODRIGUEZ-PAREDES M, ESTELLER M. Cancer epigenetics reaches mainstream oncology [J]. Nat Med, 2011, 17(3): 330-9.
[21] STRAHL B D, ALLIS C D. The language of covalent histone modifications [J]. Nature, 2000, 403(6765): 41-5.
[22] HERMANSEN N. Prognostic studies in multiple myeloma with emphasis on genetic tumor lesions [J]. 2016.
[23] NARLIKAR G J, SUNDARAMOORTHY R, OWEN-HUGHES T. Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes [J]. Cell, 2013, 154(3): 490-503.
[24] CLAPIER C R, CAIRNS B R. The biology of chromatin remodeling complexes [J]. Annu Rev Biochem, 2009, 78: 273-304.
[25] MUSSELMAN C A, MANSFIELD R E, GARSKE A L, et al. Binding of the CHD4 PHD2 Finger to Histone H3 is Modulated by Covalent Modifications [J]. Biophys J, 2010, 98(3): 475a-a.
[26] WANG Y Z, LIN X, GONG X, et al. Atypical GATA transcription factor TRPS1 represses gene expression by recruiting CHD4/NuRD(MTA2) and suppresses cell migration and invasion by repressing TP63 expression [J]. Oncogenesis, 2018, 7.
[27] LAI A Y, WADE P A. Cancer biology and NuRD: a multifaceted chromatin remodelling complex [J]. Nat Rev Cancer, 2011, 11(8): 588-96.
[28] SHAO S M, CAO H W, WANG Z K, et al. CHD4/NuRD complex regulates complement gene expression and correlates with CD8 T cell infiltration in human hepatocellular carcinoma [J]. Clin Epigenetics, 2020, 12(1).
[29] FUJITA N, JAYE D L, GEIGERMAN C, et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation [J]. Cell, 2004, 119(1): 75-86.
[30] WILSON C L, MANN D A, BORTHWICK L A. Epigenetic reprogramming in liver fibrosis and cancer [J]. Adv Drug Deliver Rev, 2017, 121: 124-32.
[31] GREER E L, SHI Y. Histone methylation: a dynamic mark in health, disease and inheritance [J]. Nat Rev Genet, 2012, 13(5): 343-57.
[32] MOHAN M, HERZ H M, SHILATIFARD A. SnapShot: Histone Lysine Methylase Complexes [J]. Cell, 2012, 149(2): 498-U259.
[33] PAGE A, PAOLI P P, HILL S J, et al. Alcohol directly stimulates epigenetic modifications in hepatic stellate cells [J]. J Hepatol, 2015, 62(2): 388-97.
[34] JOVEL J, LIN Z, O'KEEFE S, et al. A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma [J]. Hepatol Commun, 2018, 2(8): 945-59.
[35] ARROWSMITH C H, BOUNTRA C, FISH P V, et al. Epigenetic protein families: a new frontier for drug discovery [J]. Nat Rev Drug Discov, 2012, 11(5): 384-400.
[36] JENUWEIN T, ALLIS C D. Translating the histone code [J]. Science, 2001, 293(5532): 1074-80.
[37] GEZER U, YORUKER E E, KESKIN M, et al. Histone Methylation Marks on Circulating Nucleosomes as Novel Blood-Based Biomarker in Colorectal Cancer [J]. Int J Mol Sci, 2015, 16(12): 29654-62.
[38] SCHWARZENBACH H, HOON D S, PANTEL K. Cell-free nucleic acids as biomarkers in cancer patients [J]. Nat Rev Cancer, 2011, 11(6): 426-37.
[39] HOLDENRIEDER S, VON PAWEL J, NAGEL D, et al. Long-term stability of circulating nucleosomes in serum [J]. Anticancer Res, 2010, 30(5): 1613-5.
[40] GENG X, FENG J, LIU S, et al. Transcriptional regulation of hypoxia inducible factors alpha (HIF-alpha) and their inhibiting factor (FIH-1) of channel catfish (Ictalurus punctatus) under hypoxia [J]. Comp Biochem Physiol B Biochem Mol Biol, 2014, 169: 38-50.
[41] SEMENZA G L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy [J]. Trends Pharmacol Sci, 2012, 33(4): 207-14.
[42] RAVAL R R, LAU K W, TRAN M G B, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma [J]. Molecular and Cellular Biology, 2005, 25(13): 5675-86.
[43] COMERFORD K M, WALLACE T J, KARHAUSEN J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene [J]. Cancer Res, 2002, 62(12): 3387-94.
[44] COMERFORD K M, WALLACE T J, KARHAUSEN J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene [J]. Cancer Res, 2002, 62(12): 3387-94.
[45] MARTIN C M, FERDOUS A, GALLARDO T, et al. Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells [J]. Circ Res, 2008, 102(9): 1075-81.
[46] KRISHNAMACHARY B, BERG-DIXON S, KELLY B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1 [J]. Cancer Res, 2003, 63(5): 1138-43.
[47] CHAE Y C, VAIRA V, CAINO M C, et al. Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming [J]. Cancer Cell, 2016, 30(2): 257-72.
[48] KEITH B, JOHNSON R S, SIMON M C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression [J]. Nat Rev Cancer, 2011, 12(1): 9-22.
[49] RAMIREZ-BERGERON D L, RUNGE A, DAHL K D C, et al. Hypoxia affects mesoderm and enhances hemangioblast specification during early development [J]. Development, 2004, 131(18): 4623-34.
[50] KEITH B, JOHNSON R S, SIMON M C. HIF1 alpha and HIF2 alpha: sibling rivalry in hypoxic tumour growth and progression [J]. Nat Rev Cancer, 2012, 12(1): 9-22.
[51] GALLIPOLI P, HUNTLY B J P. Histone modifiers are oxygen sensors [J]. Science, 2019, 363(6432): 1148-+.
[52] SUN S R, NING X X, ZHANG Y Q, et al. Hypoxia-inducible factor-1 alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition [J]. Kidney Int, 2009, 75(12): 1278-87.
[53] BEYER S, KRISTENSEN M M, JENSEN K S, et al. The Histone Demethylases JMJD1A and JMJD2B Are Transcriptional Targets of Hypoxia-inducible Factor HIF [J]. J Biol Chem, 2008, 283(52): 36542-52.
[54] FU L N, CHEN L S, YANG J, et al. HIF-1 alpha-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism [J]. Carcinogenesis, 2012, 33(9): 1664-73.
[55] NAKAGAWA T, GUARENTE L. Sirtuins at a glance [J]. J Cell Sci, 2011, 124(6): 833-8.
[56] WANG R H, ZHENG Y, KIM H S, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis [J]. Mol Cell, 2008, 32(1): 11-20.
[57] PETERS C J, REES J R E, HARDWICK R H, et al. A 4-Gene Signature Predicts Survival of Patients With Resected Adenocarcinoma of the Esophagus, Junction, and Gastric Cardia [J]. Gastroenterology, 2010, 139(6): 1995-U280.
[58] GARBER M E, TROYANSKAYA O G, SCHLUENS K, et al. Diversity of gene expression in adenocarcinoma of the lung [J]. P Natl Acad Sci USA, 2001, 98(24): 13784-9.
[59] LEE J Y, PARK J H, CHOI H J, et al. LSD1 demethylates HIF1 alpha to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis [J]. Oncogene, 2017, 36(39): 5512-21.
[60] CAMUZI D, DE AMORIM I S S, PINTO L F R, et al. Regulation Is in the Air: The Relationship between Hypoxia and Epigenetics in Cancer [J]. Cells-Basel, 2019, 8(4).
[61] LIU Y X, LI Q Z, CAO Y N, et al. Identification of key genes and important histone modifications in hepatocellular carcinoma [J]. Comput Struct Biotec, 2020, 18: 2657-69.
[62] XIA L M, HUANG W J, BELLANI M, et al. CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes [J]. Cancer Cell, 2017, 31(5): 653-+.
[63] SIMS J K, WADE P A. Mi-2/NuRD complex function is required for normal S phase progression and assembly of pericentric heterochromatin [J]. Mol Biol Cell, 2011, 22(17): 3094-102.
[64] POLO S E, KAIDI A, BASKCOMB L, et al. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4 [J]. Embo J, 2010, 29(18): 3130-9.
[65] ORANG A V, PETERSEN J, MCKINNON R A, et al. Micromanaging aerobic respiration and glycolysis in cancer cells [J]. Mol Metab, 2019, 23: 98-126.
修改评论